Ir presentation 062314

Empowering Personalized Cancer Treatment

Summer 2014

062314

2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 2

Forward-Looking Statement

This presentation contains forward-looking statements within the meaning of the Private Securities

Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results,

future growth in research, technology, clinical development and potential opportunities for Cancer

Genetics, Inc. products and services or Gentris, Inc. products and services., along with other

statements about the future expectations, beliefs, goals, plans, or prospects expressed by

management constitute forward-looking statements. Any statements that are not historical fact

(including, but not limited to, statements that contain words such as "will," "believes," "plans,"

"anticipates," "expects," "estimates") should also be considered to be forward-looking statements.

Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent

in the development and/or commercialization of potential products, risks of cancellation of customer

contracts or discontinuance of trials, risks that we will not reach agreement on definitive acquisition

agreements with Gentris, or that the Gentris and/or BioServe transactions will not close or, if either or

both closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials

or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property

rights and other risks discussed in the Company's Form 10-K for the year ended December 31, 2013

and 10-Q for the quarter ended March 31, 2014 along with other filings with the Securities and

Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer

Genetics disclaims any obligation to update these forward-looking statements.


2013 Was a Year of Significant Progress and 2014 Shows Continued Success

54% full year revenue growth 2013 over 2012 and 45% growth Q1, 2014 over Q1, 2013.

Test volume grew 63% to 10,771 tests in 2013 over 2012 and 45% to 2,772 tests in Q1, 2014 over Q1, 2013.

Tripled Gross-Profit Margins to 26% in 2013.

Closed 2 follow-on offerings on NASDAQ totaling ~$60+ Million.

Launched 6 proprietary genomic-based diagnostic tests for lymphomas (CLL/SLL, DLBCL, FL, MCL), kidney cancer and cervical

cancer.

Launched the CALR mutation analysis test targeting ~3 Million patients in the US with MPN.

Received 3 patent awards covering CGI’s diagnostics for hematologic and kidney cancers.

Expanded key biopharma relationships with Gilead and Roche driving adoption of CGI’s genomic tests nationally and

internationally.

Progressive advancements to the management team and board of directors with

experienced and seasoned industry leaders.

Expanded collaborations and partnerships with world-class institutions including

J.V. with Mayo Clinic in Generation Sequencing: OncoSpire Genomics.


Molecular Diagnostics are Changing our Understanding of Cancer While Providing New Tools to Diagnose & Treat Patients

Our unique focus & approach supports the entire cancer care continuum

Personalize

therapeutic plan and

treatment options

DIAGNOSIS PROGNOSIS THERANOSIS

Assist in patient

outcome and disease

management

What drug(s) to give, how

much, and when?

What are my survival

prospects?

Do I have cancer and

what type?

Use genomics to provide

an accurate and definitive

typing of the cancer

Proprietary Products Focused Oncology Lab Comprehensive Report

Integrated Molecular Diagnostic Testing Brings Benefits

Across the Entire Oncology Ecosystem


CGI’s Mission is to Personalize and Improve the Success Rate in Cancer Treatment

Integrating & Delivering Genomic Information About a Patient’s Cancer

Can Improve Care & Reduce Cost

Phenotypic &

Physical Examination

Morphologic &

Pathological Analysis

Large & Multiple

Specimens Required

Significant Delays to

Treatment

Traditional Approach

Biomarkers and

Companion Diagnostics

Genomic Analysis &

Proprietary Algorithms

Reduced Size and

Number of Specimens

Improved Diagnoses &

Treatment Plans

Our Approach: Personalized Medicine

Target For Tomorrow

25%

Situation Today Source: Clinical Trends in Molecular Medicine, Vol. 7, Issue 5

100%

Success Rate Target Success Rate


The Acquisitions of BioServe India and Gentris Corporation Provide Significant Market Upside & Improve CGI’s Competitive Position

• Access to high-growth Indian diagnostics

market – projected to grow at 15-20% per

annum for the next decade.

• Accelerates next-generation sequencing

development and validation of targeted hot

spot oncology panels.

• Cost-effective expansion of genomic

analysis & informatics capabilities with state

of-the-art 14,000 sq. foot lab.

BioServe India

• Growth potential in integrating our oncology-

focused testing capabilities with Gentris’

high-value contracts.

• Expansion of Gentris’ capabilities and

portfolio to include oncology-focused

pharmacogenomics services.

• 24,000 sq. foot lab space (CLIA/CAP/GLP)

with NGS, genotyping, and gene expression

test capabilities.

Gentris Corporation


Unique, Scalable and Multifaceted Business Model With A Focus On Providing A Complete Solution

Suite of Products and Services Provides Multiple Growth Drivers and Value to Multiple Parties:

Clinical Community, Biopharma & Medtech

CLINICAL SERVICES

Differentiated and complete

disease-focused solutions

Superior turnaround times

World-class expertise in

genomics and cytogenetics

Serving community hospitals and

labs through unique Expand Dx™

program

BIOPHARMA PARTNERSHIPS

Biomarker and companion

diagnostic development

World-class genomics and

bioinformatics

Drug-specific and cancer-

specific assays

Comprehensive focus in

hematologic and urogenital

cancers

PROPRIETARY PRODUCTS

Proprietary molecular

diagnostics & FISH probes

Clinically validated

IP-protected

Sold globally

Probe manufacturing leverages

low-cost, high scale facility in

India


Our Target Markets in Oncology Testing Comprise Over 615,000 New Lives Annually in the U.S.

Ability to Impact Over 615,000 New Lives Annually in the U.S.

Source: American Cancer Society

156,420 2014 Estimated New Cases

(U.S.)

Death Rate 35%

Hematological: Lymphoma, Leukemia, M. Myeloma


(U.S.)

Death Rate 16%

Urogenital: Kidney, Bladder & Prostate


(U.S.)

Death Rate 31%

Gynecological: Cervical, Endometrial & Ovarian

6 Products Launched in Target Segments

Over $6Bn in Annual U.S. Spend on Lab Testing In These Categories


6 Proprietary Diagnostic Products Commercially Launched & In Market

Incidence Indication

Lymphoma & Leukemia Microarrays (MatBA®)

106,770 (Annual New Cases, Global)

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma


Diffuse Large B-Cell Lymphoma


Follicular Lymphoma


Mantle Cell Lymphoma

Kidney Cancer Microarray (UroGenRA®)


Kidney Cancer

Cervical Cancer DNA-FISH Probe (FHACT®)

1,750,000 (Annual New Cases, US)

HPV+ Low Grade Cervical Lesions

Over 2.3 Mn Combined Annual New Cases Globally


Product Pipeline

Research &

Discovery

Clinical

Development

Commercial

Development

Launch &

Market Entry

Indication

Development Stage

Lymphoma & Leukemia Microarrays (MatBA®)

Multiple Myeloma

Bladder and Prostate Cancer Microarrays (UroGenRA®)

Bladder Cancer

Prostate Cancer

HPV-Associated Cancer DNA-FISH Probe (FHACT®)

Head & Neck Cancer

Urogenital Cancer Microarrays (UGenRA™)

Cervical Cancer

Endometrial Cancer

Ovarian Cancer


Despite Improved Cancer Care, Case Numbers for Hematologic Cancers are Still Rising

Genomics-Based Tests like MatBA® are Critical and Improve

the Management and Cost of Hematologic Cancers

Source: Genzyme & Nature Source: National Cancer Institute, National Center for Health Statistics, SEER

Dataset of Incidence & Mortality, FDA

1 2 5 12

89

100 80 60 30 2

Number of Years Ago

11.1 12.6

15.5

18.5 20.0 19.7

20.5 21.2

5.6 6.2 7.1

7.9 8.7 8.2

6.9 7.3

1975 1980 1985 1990 1995 2000 2005 2010

Incidence Rate Survival Rate

Identified Leukemia & Lymphoma Subtypes Incidence & Survival Rates for NHLs (US Only, per 100,000)


MatBA®-CLL/SLL Improves Risk Stratification & Outcome Prediction

Validated in Collaboration w/ Dr. Kanti Rai & Dr. Nicholas Chiorazzi (NSLIJ); 2 Datasets, 322 specimens

Additional Validations being conducted w/ HUMC & Dana Farber; 2 Cohorts, 350+ specimens

█ Favorable

█ Intermediate

█ Unfavorable

█ Favorable/

Intermediate

(no distinction)

38% of cases in our study have

a favorable prognosis falling

under "watch & wait" approach.

8% of cases with unfavorable

prognosis missed by FISH and

caught using MatBA®-CLL/SLL.

Impact on therapy selection &

clinical management of CLL

patients.

Genomic Aberrations Reported

by FISH:

4

Genomic Aberrations Reported

by MatBA®-CLL/SLL:

20

85%

15%

FISH

23%

39%

38%

(Current Method) (CGI Method)


MatBA® can Group Patients into Risk Groups & Prognostication Classes

MatBA®- CLL / SLL is a diagnostic tool and

prognostic indicator for patient stratification

and improved patient management

Being actively used in clinical care, in clinical trials and in

validation programs with Dana Farber, MSKCC and

HUMC

20 key genetic events/sites classify CLL patients as

having the potential for

Poor outcome = High risk

Intermediate outcome = Intermediate risk

Good outcome = Low risk

Detection of specific genomic imbalance in

CLL/SLL by MatBA®-CLL/SLL correlates

patient risk with time to first treatment

(TTFT) and shorter overall survival (OS)

Patients classified as high risk showed a shorter TTFT

compared to those classified as low or intermediate risk

Patients classified as high risk had significantly shorter OS

times than those classified as low or intermediate risk

Provides additional risk stratification between low and

intermediate risk patients, not currently available in other

tests

Time to First Treatment (TTFT)

Time (months)

Time (months)

Pro

po

rtio

n

Su

rviv

ing

P

rop

ort

ion

Tre

atm

en

t-F

ree

– GOOD (n=74)

– INTERMED (n=107)

– POOR (n=47)

– GOOD (n=74)

– INTERMED (n=107)

– POOR (n=47)

P = 0.090

P = 0.001

P < 0.001

P = 0.010

Overall Survival (OS)

Leukemia & Lymphoma – Houldsworth, et. al Sept. 18, 2013


UroGenRA®-Kidney Can Guide Management of Patients with Renal Masses and Appropriate Treatment Selection

Clinical Benefits Include Reduction in Number of Highly Invasive Procedures and Time to

Treatment Initiation, and Better Informed Treatment Selection

Development of diagnostic algorithm

>600 RCC malignant subtypes (in-silico: SNP)

>100 malignant and benign renal neoplasms (in-house: aCGH & FISH)

Retrospective in-house FFPE validation (n>190) CCF

100% diagnostic yield

97% diagnostic sensitivity to distinguish benign from malignant renal neoplasms

93% sensitivity to distinguish malignant RCC subtypes

C. Magi-Galluzzi and E. Klein (Cleveland Clinic)

Prospective ongoing percutaneous core needle biopsy (n>50) MSKCC

Demonstrated ability to diagnose pathologically “unclassifiable” biopsies prior to surgical

intervention

J. Coleman and J. Durack (MSKCC)

PROBLEM

Men and women with renal masses often

undergo unnecessary nephrectomy for

accurate diagnosis and experience delay in

treatment

SOLUTION

UroGenRA® will detect genomic aberrations in a single assay

permitting accurate diagnosis (benign vs malignant, and

malignant subtype) guiding appropriate management and

treatment strategies


FHACT® - A New Genomic Aid In The Screening & Management Of Cervical Cancer

FHACT® Provides Critical Information Which Reduces

Unnecessary and Costly Colposcopies

Cervical cancer effects nearly 500,000 women globally each year with

nearly 80% in developing countries.

Today, all these women are

referred for colposcopy.

Women with abnormal or unclear Pap smears

55 Million Pap smears per year

3.5 Million Pap smears come back

as unclear/abnormal

2 Million biopsies performed

12,000 cases of cervical cancer


FHACT® Provides Information for Developing Treatment Plans Potentially Reducing Healthcare Costs & Procedures

FHACT® is the Only 4 Color FISH Probe that can be Used for Cervical Cancer Screening

as Additional Testing Before Referral for Colposcopy

Global Validation Partners Genomic Amplification by Disease Category

Source: P. Luhn, J. Houldsworth, et al., Gynecologic Oncology (2013)

5 10 19 20

0

20

40

60

80 ptrend = 0.01

6 9 9 20

0

20

40

60

80 ptrend = 0.02

6 9 7 12 0

20

40

60

80 ptrend = 0.03

3 8 12 12 0

20

40

60 ptrend = 0.001

<CIN2

& NLIM

(n=11)

<CIN2

& LSIL

(n=20)

CIN2

&/or HSIL

(n=10)

CIN3+

(n=7)

<CIN2

& NLIM

(n=11)

<CIN2

& LSIL

(n=20)

CIN2

&/or HSIL

(n=10)

CIN3+

(n=7)

FHACT® detects irreversible changes in

cervical cells caused by HPV.


Large, Targeted Market Opportunities

Target Markets Commercialization Strategy

Community Hospitals

Regional Cancer Centers

Oncologists and Pathologists

Continue to growing sales force that calls on hospitals

and regional laboratories

Plan development of national footprint through Expand

Dx™

Biotechnology Companies

Pharmaceutical Companies

Leverage clinical infrastructure and proprietary product

portfolio for testing services that support clinical trials

Expand sales emphasis of Select One®

Emerging Markets

Enhance distributor base in select emerging economies

Partner with leading local cancer care providers and

hospitals to provide probes, arrays and clinical services

Collaborate to create and validate microarrays and other

proprietary products

Accelerate launch of large scale studies

Universities and Research Centers


Unique Service Offering Developed to Enable Community Hospitals to Improve Cancer Outcomes & Treat Patients Locally

Delivers better outcomes to

community hospitals and laboratories

Enables community hospitals to bring

“state-of-the-art” genomic testing to

patients

Brings personalized medicine to the

community hospital vs. just at

academic and teaching hospitals

Allows community hospitals to keep

patients and treat them locally

Improving care and quality is critical to

maintaining reimbursement for

community hospitals

$600,000 - $800,000 USD in Testing

Opportunity on Average per Hospital

Expanding & Developing Cancer Care is a

Top Priority for Hospital CEOs & CFOs

4,000 to 5,000 Community Hospitals

& Laboratories in the U.S.

85% Of All U.S. Cancer Patients are Initially

Diagnosed in Community Hospitals &

Laboratories


Through Acquisition, Clinical Trial Services Show Strong Growth and Robust Pipeline

Gentris Provides Pharmacogenomic Clinical Trial Services to Several Large Pharma

Companies Including Merck, Novartis, Otsuka, Eisai and Bristol-Myers Squibb

GROWTH IN CGI’s SELECT ONE®

CONTRACTS ($000)

21%

55%

ONCOLOGY DRUGS ASSOCIATED WITH

BIOMARKER(S)

$300

$2,700

$8,500

$14,200

2011 2012 2013 2014

Approximate value of contracts with biotech and pharma clients

2011 2016

Source: Company Analysis and Management Estimates


Over 6,800 Oncology Trials in the US Aligned with our Core Markets

Number of Open Clinical Trials (U.S.)

1,439 1,453

2,178

1,765

Lymphoma Leukemia Urogenital HPV-Associated

Source: www.clinicaltrials.gov


Gilead is Currently Using a Comprehensive Panel of CGI Services & Proprietary Products in National & International Trials for

Hematologic Cancers

The Gilead Relationship Exemplifies the Significant Upside Potential of

CGI’s Select One® Offering

Highlights

Comprehensive, biomarker-based patient profiling will help risk stratification and response monitoring

Improved patient profiling will result in improved trial efficacy for Gilead

Testing will occur across several methodologies, including flow cytometry, FISH, sequencing and

mutation assays, and MatBA® microarrays

CGI provides biomarker driven insight regarding patient targeting and potential outcomes

Trials cover both national and international locations with all patient specimens being processed in

Rutherford, New Jersey

CGIX Press Release: Cancer Genetics, Inc. Selected By Gilead Sciences, Inc. to Provide Clinical Trial Services for International Trials in Chronic Lymphocytic Leukemia


Roche Partnership Expanding Market Presence Internationally

“By expanding our relationship, we are strengthening our ability to provide patients the best

service possible.” Alvaro Soto, Roche Servicios, Central America & Caribbean General Manager

Highlights

CGI provides genomic and biomarker testing services to 14 countries

in Central America and the Caribbean.

CGI won a global RFP to help a strategic personalized medicine initiative for Roche Servicios (Latin

America)

Roche sends all patient samples to the Rutherford facility where they are catalogued and processed

CGI interacts with both Roche and the hospital staff (pathologists, oncologists and nurses) and

supports delivery of reports through an online HIPAA compliant portal

CGI and Roche expanded this relationship in 2013 and will begin developing workshops and training

programs to drive adoption of biomarker-based cancer diagnostics throughout Central America and

the Caribbean

CGI and Roche recently further expanded this relationship with an exclusive multi-year deal in which

CGI will develop a center of excellence for lung cancer testing utilizing Roche’s FDA-Approved

cobas® platform

CGIX Press Release: Cancer Genetics, Inc. selected by Roche Servicios S.A. to provide services for the diagnosis and personalization of oncology treatment

CGIX Press Release: Cancer Genetics, Inc. expands relationship with Roche Servicios S.A.


Collaborations with Premier Cancer Research Institutions Leading Differentiated Research & Driving Product Adoption

Research Collaboration/

Licensing

Clinical

Services

Partnership

Highlights

Kidney Cancer, DLBCL, MCL & FL

Joint Venture Focused on Oncology & Next

Generation Sequencing

Cervical Cancer

DLBCL

CLL

Cervical Cancer & DLBCL

Cervical Cancer

Kidney Cancer

DLBCL, Head & Neck Cancers

CLL


Mayo Clinic Joint Venture Investing in the Future – OncoSpire Genomics

The Value and Focus of Next Generation Sequencing is Moving from Platforms to Clinically

Relevant, Disease-Specific Applications

Highlights

JV, based in Rochester, MN, will develop clinical diagnostic products and services on NGS platform(s)

in areas of high clinical need

Three initial projects in key oncology categories selected by the SRC (Scientific Review Committee):

Lung Cancer, Multiple Myeloma, Follicular Lymphoma

CGI commits up to $6 M over initial three year period (2013 to 2015-16 expected)

Mayo commits to “in-kind” services and support, use of facilities, NGS capabilities and access to

biorepository

Joint Venture is exclusive in the project areas selected by CGI & Mayo

Important company update and analyst day held November 22, 2013

Next Generation Sequencing in Oncology


OncoSpire Genomics Projects are Unique and Have High Value

1.6 million

new cases

200,000

new cases

20,920

new cases

Informed

Discovery

Clinical

Development

Commercial

Development

Market Entry

(with partners)

Lung Cancer

Multiple Myeloma

Follicular Lymphoma

Selected Projects Have Significant Clinical Value & May Yield Multiple Focused

Panels to Become the Standard of Care in NGS-Based Oncology Management


Strong History of Growth CGI Revenue & Clinical Volume Trends (2009 – 2013)

54% Full Year 2013 Revenue Growth

$1.67

$2.52

$3.02

$4.30

$6.61

2009 2010 2011 2012 2013

2,321

3,146 3,622

6,610

10,771

2009 2010 2011 2012 2013

Total Revenue ($Mn) Clinical Volume (Tests Processed)


Strong History of Growth - Revenue & Clinical Volume Trends (Q1 Comparison 2012-2014)

$835

$1,219

$1,430

Q1, 2012 Q1, 2013 Q1, 2014

Total Revenue ($000)

1,610

1,911

2,772

Q1, 2012 Q1, 2013 Q1, 2014

Clinical Volume (Tests Processed)


Summary Statement of Operations (Q1 Comparison 2012-2014)

Income Statement Item Q1, 2012 Q1, 2013 Q1, 2014

Revenue $835 $1,219 $1,430

Gross Profit 12 149 140

Gross Margin (%) 1.4% 12.2% 9.8%

Research & Development (R&D) 524 491 597

Sales & Marketing (S&M) 340 396 749

General & Administrative (G&A) 936 1,571 2,731

Operating Profit (Loss) (1,788) (2,309) (3,937)

Net Income (Loss) (1,072)

2,360

(2,486)

$ in thousands

Actual 03/31/14

Cash & Cash Equivalents $41,315

Stockholders’ Equity 43,635

$ in thousands

Summary Balance Sheet


Consistent Focus on Gross Profit Improvements Additional Efforts Focused Operationally in US & India

Gross Profit Margin Highlights of Initiatives

(52%) (39%) (3%)

9%

26%

(1,000)

(800)

(600)

(400)

(200)

0

200

400

600

800

2009

2010

2011

2012 2013

$ in T

housands

Decrease CGI Costs for

Development & Services

Migrate DNA manufacture and

NT Kits for CGI probes

Develop remove G-Band analysis

capability

Develop remote FHACT®

analysis capabilities

Move entire probe manufacturing

& assembly


Multiple Customer Types Provide Diversified Revenue Mix With Covered Lives Already in Place

Selected Payors

Direct Bill Customer Types

Biotechs

Pharmas

Academic

Cancer Facilities

Community &

Regional Labs

72+ million covered lives through multiple payors:

13%

21% 58%

3% 5%

Medicare

3rd Party

Insurance Companies,

Hospitals

& Care

Facilities

Payor Revenue Mix 2013

Reimbursement Based Direct Bill / Pay Based

3rd Party Insurance

Medicare Grants

2013

Probes

Companies, Hospitals

& Care Facilities


Experienced and Focused Management and Boards

Scientific Advisory Board

Andrea Califano, Ph.D. Chairman of the Columbia Initiative for Systems Biology

Associate Director for Bioinformatics, Herbert Irving Comprehensive

Cancer Center

Timothy A. Chan, M.D., Ph.D. Principal Investigator, Human Oncology and Pathogenesis Program

at Memorial Sloan-Kettering Cancer Center

Riccardo Dalla-Favera, M.D. Director, Institute for Cancer Genetics at Columbia University

Hans-Guido Wendel, M.D. Principal Investigator, Cancer Genetics Laboratory at Memorial

Sloan-Kettering Cancer Center

Vundavalli V. Murty, Ph.D. Director, Cancer Cytogenetic Laboratory and Molecular Pathology at

Columbia University

Andrew D. Zelenetz, M.D., Ph.D. Chief of Lymphoma Service and Head of Molecular Hemo-Oncology

Laboratory, Department of Medicine at MSKCC

Raju Chaganti, Ph.D., FACMG Founder

• 35+ years in cancer research; 38 at MSKCC

• Major discoveries in cancer genomics

• Published 350+ articles, 4 patents

Panna Sharma President & CEO

• 15+ years as advisor to global life science & healthcare cos.

• Founded TSG Partners

• Chief Strategy Officer, iXL (IIXL)

Edward J. Sitar Chief Financial Officer & Treasurer

• 30+ yrs in finance & deal making in the healthcare industry

• Healthagen, ActiveHealth Management, Cadent Holding, MIM Corporation

(Bioscrip), Vital Signs, Zenith/Goldline Pharmaceutical, Coopers &

Lybrand

Jane Houldsworth, Ph.D. Vice President of R&D

• 25+ years in translational oncology research

• Published 50+ articles, 4 patents

• NIH grantee

Chairman of the Board, | Keith Brownlie, CPA | Edmund Cannon | Raju Chaganti, Ph.D.

John Pappajohn | Franklyn Prendergast, M.D., Ph.D. | Paul Rothman, M.D. | Panna Sharma

Board of Directors

Officers & Management Team


Consistent Achievement of Milestones Expected in Coming Quarters

Increasing covered lives market access through

additional payers & health care organizations

Launching multi-marker NGS panel for lymphoid

malignancies

Additional international agreements with life science

tools companies for DNA Probes and product

distribution in key geographies

MatBA® – Next phase of data and results from Dana

Farber and HUMC studies to help support value and

reimbursement

Pursuing CE approval for IVDD use of FHACT® in

E.U.

Additional news on biopharma partners &

relationships

Pursuing additional indications for UroGenRA®-

Kidney microarray

Portfolio and analyst update meeting (June)

Close of BioServe transaction (Q3, 2014)

Accelerating Market Traction – 54% growth during 2013 over 2012

Migrated DNA-FISH Probe Manufacturing to India reducing cost, increasing

capacity and improving operational flexibility

Launched UroGenRA®-Kidney, a unique microarray for kidney cancer

diagnosis in collaboration with MSKCC

Collaborative Study of UroGenRA®-Kidney with Cleveland Clinic

demonstrated 93% diagnostic accuracy

Launched FHACT® outside the U.S. in collaboration with the National

Cancer Institute research publication

Launched FHACT® as an LDT under CLIA in the U.S.

Received CLIA Approval for MatBA®-MCL (Mantle Cell Lymphoma)

Finalized Agreement with Multiplan and Three Rivers which gave us

access to 72+ million covered lives

Launched OncoSpire Genomics – A Next Generation Sequencing Joint

Venture with Mayo Clinic and announced initial set of projects (lung cancer,

multiple myeloma & follicular lymphoma)

Recent

Accomplishments Upcoming Milestones

and Value Drivers

For further information, please contact us at [email protected]

Cancer Genetics, Inc.

Meadows Office Complex

201 Route 17 North

Rutherford, NJ 07070

(201) 528-9200

www.cancergenetics.com

Appendix


IP Position and Detailed Global Strategy

Strong and growing portfolio in molecular-focused patents for disease

identification and stratification

IP-based on unique algorithms across a broad group of chromosomal regions

Validation of specific clinical endpoints that are associated with

particular disease outcomes or decisions

Filing and maintenance of trademark portfolio

Tool for Diagnosis and Prognosis of Mature B-Cell Neoplasms US Issued Patent 8,580,713 US Issued Patent 8,557,747 Europe 10803548.6 India 6657/DELNP/2012 Canada 2,785,656

Methods of Analyzing Chromosomal Translocations Using Fluorescence In Situ Hybridization (FISH)

US Issued Patent 7,585,964 US Issued Patent 7,964,345 Canada 2,447,320

Panel for the Detection and Differentiation of Renal Cortical Neoplasms

US Issued Patent 8,603,948 US 14/078,726 Europe 08844570.5

Methods for Detecting Human Papilloma Virus-Associated Cancers

US 13/227,027 US 13/474,111 PCT/US2011/050681

Methods and Tools for the Diagnosis of Female Gynecological Cancers and Precancers

US 61/581,350


BioServe India – Profile & Capabilities

Cutting-Edge Genomic Services:

Next Generation Sequencing, Genotyping & DNA Synthesis

Founded in 2002 and located in Hyderabad, Andhra Pradesh.

14,000 square foot NABL* accredited facility for its GMO services, equipped

with NGS capabilities.

33 employees including 19 scientific staff members and 7 in sales.

Has developed next generation sequencing panels for oncology.

Infrastructure and scientific expertise required to integrate CGI’s DNA-FISH

probe manufacturing and proprietary FHACT® business into the Indian

biotech market that accounts for >25% of global cervical cancer deaths.

Current customers include Center for Cellular and Molecular Biology, Center

for DNA Finger Printing and Diagnostics and Dr. Reddy's labs.

Backed by VenturEast, a pioneering healthcare-focused venture capital fund

manager based in India with ~$300 Million under management.

$65 Bn

$100 Bn

2013 2015

Indian Healthcare Sector

Dx & Medical Equipment

$3.3 Bn

$5 Bn

2013 2015

15-20%

Growth

Source: PM Live Pharmaceutical

Industry News & KPMG

*NABL: National Accreditation Board for Testing and Calibration Laboratories (equivalent to CLIA).

Health & Medicine

Ir presentation 062314